Stockreport

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

Delcath Systems, Inc.  (DCTH) 
US:NASDAQ Investor Relations: delcath.com/investors
PDF NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary [Read more]